SG11201911930SA - Methods and compositions for substance use disorder vaccine formulations and uses thereof - Google Patents

Methods and compositions for substance use disorder vaccine formulations and uses thereof

Info

Publication number
SG11201911930SA
SG11201911930SA SG11201911930SA SG11201911930SA SG11201911930SA SG 11201911930S A SG11201911930S A SG 11201911930SA SG 11201911930S A SG11201911930S A SG 11201911930SA SG 11201911930S A SG11201911930S A SG 11201911930SA SG 11201911930S A SG11201911930S A SG 11201911930SA
Authority
SG
Singapore
Prior art keywords
compositions
methods
vaccine formulations
substance use
use disorder
Prior art date
Application number
SG11201911930SA
Inventor
Kim Janda
Ho Sam On
Gary Fujii
Original Assignee
Molecular Express Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Express Inc filed Critical Molecular Express Inc
Publication of SG11201911930SA publication Critical patent/SG11201911930SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/54—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6012—Haptens, e.g. di- or trinitrophenyl (DNP, TNP)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
SG11201911930SA 2017-06-11 2018-06-11 Methods and compositions for substance use disorder vaccine formulations and uses thereof SG11201911930SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762517973P 2017-06-11 2017-06-11
PCT/US2018/036904 WO2018231706A1 (en) 2017-06-11 2018-06-11 Methods and compositions for substance use disorder vaccine formulations and uses thereof

Publications (1)

Publication Number Publication Date
SG11201911930SA true SG11201911930SA (en) 2020-01-30

Family

ID=64659330

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201911930SA SG11201911930SA (en) 2017-06-11 2018-06-11 Methods and compositions for substance use disorder vaccine formulations and uses thereof

Country Status (6)

Country Link
US (2) US20200115324A1 (en)
AU (1) AU2018283973A1 (en)
CA (1) CA3066915A1 (en)
PH (1) PH12019550275A1 (en)
SG (1) SG11201911930SA (en)
WO (1) WO2018231706A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3066915A1 (en) 2017-06-11 2018-12-20 Molecular Express, Inc. Methods and compositions for substance use disorder vaccine formulations and uses thereof
CA3158029A1 (en) * 2019-10-17 2021-04-22 Children's Medical Center Corporation Tlr7/8 agonists to enhance immune responses in opioid using individuals
CN111643661A (en) * 2020-06-08 2020-09-11 王竹林 Novel immunologic adjuvant, compound and application thereof
CN116082180A (en) * 2022-12-30 2023-05-09 中科禾一（大连）农业科技有限公司 Tobacco source alkaloid and preparation method thereof

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4329281A (en) * 1978-06-05 1982-05-11 Hoffmann-La Roche Inc. Hapten compositions
US4286592A (en) 1980-02-04 1981-09-01 Alza Corporation Therapeutic system for administering drugs to the skin
US4314557A (en) 1980-05-19 1982-02-09 Alza Corporation Dissolution controlled active agent dispenser
US4379454A (en) 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4568343A (en) 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US5352449A (en) 1986-05-30 1994-10-04 Cambridge Biotech Corporation Vaccine comprising recombinant feline leukemia antigen and saponin adjuvant
US4767402A (en) 1986-07-08 1988-08-30 Massachusetts Institute Of Technology Ultrasound enhancement of transdermal drug delivery
US4948587A (en) 1986-07-08 1990-08-14 Massachusetts Institute Of Technology Ultrasound enhancement of transbuccal drug delivery
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4868132A (en) * 1987-02-03 1989-09-19 Abbott Laboratories Fluorescence polarization immunoassay for amphetamine/methamphetamine
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4780212A (en) 1987-07-31 1988-10-25 Massachusetts Institute Of Technology Ultrasound enchancement of membrane permeability
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
GB2232892B (en) 1988-02-23 1991-07-24 John Mark Tucker Occlusive body for administering a physiologically active substance
ATE115862T1 (en) 1989-02-04 1995-01-15 Akzo Nobel Nv TOCOLE AS A VACCINE ADJUVANT.
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649013B1 (en) 1989-07-03 1991-10-25 Seppic Sa VACCINES AND VECTORS OF FLUID ACTIVE INGREDIENTS CONTAINING METABOLIZABLE OIL
FR2649012B1 (en) 1989-07-03 1991-10-25 Seppic Sa INJECTABLE MULTIPHASIC EMULSIONS
US5464387A (en) 1991-07-24 1995-11-07 Alza Corporation Transdermal delivery device
US5273965A (en) 1992-07-02 1993-12-28 Cambridge Biotech Corporation Methods for enhancing drug delivery with modified saponins
CA2139756A1 (en) 1992-07-08 1994-01-20 Eric M. Bonnem Use of gm-csf as a vaccine adjuvant
DE69331805T2 (en) 1992-12-10 2002-11-28 Enzon Inc GLYCOLIPID ENZYME-POLYMER CONJUGATES
US6251687B1 (en) 1993-09-24 2001-06-26 Biosite Diagnostics, Inc. Fluorescence energy transfer and intramolecular energy transfer in particles using novel compounds
US6238931B1 (en) 1993-09-24 2001-05-29 Biosite Diagnostics, Inc. Fluorescence energy transfer in particles
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
DE69434745T2 (en) 1993-11-02 2006-10-05 Matsushita Electric Industrial Co., Ltd., Kadoma Method for producing an aggregate of micro-needles made of semiconductor material and method for producing a semiconductor component with such an aggregate
US5814599A (en) 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
US5885211A (en) 1993-11-15 1999-03-23 Spectrix, Inc. Microporation of human skin for monitoring the concentration of an analyte
US5458140A (en) 1993-11-15 1995-10-17 Non-Invasive Monitoring Company (Nimco) Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers
DE9319879U1 (en) 1993-12-23 1994-03-17 Inventa Ag Sequentially co-extruded coolant line
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5457041A (en) 1994-03-25 1995-10-10 Science Applications International Corporation Needle array and method of introducing biological substances into living cells using the needle array
US5591139A (en) 1994-06-06 1997-01-07 The Regents Of The University Of California IC-processed microneedles
US5730990A (en) 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DK0772619T4 (en) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunomodulatory oligonucleotides
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5876727A (en) * 1995-03-31 1999-03-02 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US5618275A (en) 1995-10-27 1997-04-08 Sonex International Corporation Ultrasonic method and apparatus for cosmetic and dermatological applications
US5656016A (en) 1996-03-18 1997-08-12 Abbott Laboratories Sonophoretic drug delivery system
US7033598B2 (en) 1996-11-19 2006-04-25 Intrabrain International N.V. Methods and apparatus for enhanced and controlled delivery of a biologically active agent into the central nervous system of a mammal
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
DE69838992T2 (en) 1997-09-05 2008-12-24 Glaxosmithkline Biologicals S.A., Rixensart Oil-in-water emulsions with saponins
GB2336310B (en) 1998-04-14 2003-09-10 Stowic Resources Ltd Method of manufacturing transdermal patches
US6322532B1 (en) 1998-06-24 2001-11-27 3M Innovative Properties Company Sonophoresis method and apparatus
US6232082B1 (en) 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction
US6685699B1 (en) 1999-06-09 2004-02-03 Spectrx, Inc. Self-removing energy absorbing structure for thermal tissue ablation
JP4162813B2 (en) 1999-10-28 2008-10-08 久光製薬株式会社 Iontophoresis device
US6974588B1 (en) 1999-12-07 2005-12-13 Elan Pharma International Limited Transdermal patch for delivering volatile liquid drugs
US7632929B2 (en) * 2000-04-20 2009-12-15 The Board Of Trustees Of The University Of Arkansas Methamphetamine-like hapten compounds, linkers, carriers and compositions and uses thereof
US6908453B2 (en) 2002-01-15 2005-06-21 3M Innovative Properties Company Microneedle devices and methods of manufacture
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
US7018345B2 (en) 2002-12-06 2006-03-28 Hisamitsu Pharmaceutical Co., Inc. Iontophoresis system
GB0425258D0 (en) * 2004-11-16 2004-12-15 Novartis Ag Organic compounds
CA3066915A1 (en) 2017-06-11 2018-12-20 Molecular Express, Inc. Methods and compositions for substance use disorder vaccine formulations and uses thereof

Also Published As

Publication number Publication date
WO2018231706A1 (en) 2018-12-20
US20200115324A1 (en) 2020-04-16
PH12019550275A1 (en) 2020-07-13
AU2018283973A1 (en) 2020-01-16
US20210107862A1 (en) 2021-04-15
US11739054B2 (en) 2023-08-29
CA3066915A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
IL265590B (en) Keratin treatment formulations and methods
IL263287A (en) Neoepitope vaccine compositions and methods of use thereof
HK1252325A1 (en) Formulations for neoplasia vaccines and methods of preparing thereof
IL253123B (en) Formulations for transdermal administration and uses thereof
ZA201805805B (en) Formulations and methods
HK1259311A1 (en) Sstr-targeted conjugates and particles and formulations thereof
FI3380525T3 (en) Pharmaceutical formulations and methods of use thereof
GB201801566D0 (en) Methods and compositions for nanormulsion vaccine formulations
SG11201911930SA (en) Methods and compositions for substance use disorder vaccine formulations and uses thereof
IL266345A (en) Dihydropyrimidine compound and preparation method and use thereof
HK1259146A1 (en) Methods and compositions for influenza vaccination
GB201721582D0 (en) S aureus antigens and immunogenic compositions
EP3256098C0 (en) Dental composition and use
HK1245113A1 (en) Pharmaceutical compositions and use thereof
IL258700A (en) Adjuvant and vaccine composition containing the same
EP3615005A4 (en) Compositions and methods for vaccine delivery
GB201703529D0 (en) Vaccine composition
EP3389786A4 (en) Thermally stable rotavirus vaccine formulations and methods of use thereof
ZA201908264B (en) Formulations of homotaurines and salts thereof
GB201716745D0 (en) New formulations and uses thereof